<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="170">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04647994</url>
  </required_header>
  <id_info>
    <org_study_id>30270820.3.0000.0068</org_study_id>
    <nct_id>NCT04647994</nct_id>
  </id_info>
  <brief_title>Exploratory Study: COVID-19 and Pregnancy</brief_title>
  <official_title>Exploratory Study in COVID-19 During Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The SARS-CoV-2 infection may behave differently in pregnant and postpartum women in the short&#xD;
      and long term. Several risk factors or medication use can interfere on disease' evolution and&#xD;
      vertical transmission. Thus, due the current pandemic and the scarcity of scientific studies&#xD;
      involving pregnant women with covid-19 or positive serology, combined with the need to&#xD;
      elucidate the behavior of this viral infection in pregnant women in our population, this&#xD;
      study aims to evaluate the clinical and laboratory evolution, transplacental passage,&#xD;
      gestational and neonatal outcomes in pregnancies with positive SARS-CoV-2.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2020</start_date>
  <completion_date type="Anticipated">June 13, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic test: SARS-CoV-2 serology</measure>
    <time_frame>01/07/2021</time_frame>
    <description>Number of pregnant women with COVID-19 infection assessed with a serology test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Laboratorial analysis of maternal and umbilical cord blood</measure>
    <time_frame>01/07/2021</time_frame>
    <description>Number of participants with transplacental passage of SARS-CoV-2 assessed by laboratorial analysis of maternal and umbilical cord blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratorial analysis of Amniotic Fluid</measure>
    <time_frame>01/07/2021</time_frame>
    <description>Number of participants with transplacental passage of SARS-CoV-2 assessed by amniotic fluid analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placenta biopsy</measure>
    <time_frame>01/07/2021</time_frame>
    <description>Number of participants with transplacental passage of SARS-CoV-2 assessed by placenta biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratorial analysis of colostrum</measure>
    <time_frame>01/07/2021</time_frame>
    <description>Number of participants with transplacental passage of SARS-CoV-2 assessed by colostrum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ovarian remains biopsy</measure>
    <time_frame>01/07/2021</time_frame>
    <description>Number of participants with transplacental passage of SARS-CoV-2 assessed by ovarian remains biopsy in cases of abortion and fetal death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood count analysis</measure>
    <time_frame>01/07/2021</time_frame>
    <description>Number of participants with adverse events assessed by the blood count analysis after SARS-CoV-2 infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratorial analysis of thyroid hormones</measure>
    <time_frame>01/07/2021</time_frame>
    <description>Number of participants with adverse events assessed by the thyroid hormones analysis after SARS-CoV-2 infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCR analysis</measure>
    <time_frame>01/07/2021</time_frame>
    <description>Number of participants with adverse events assessed by the PCR analysis after SARS-CoV-2 infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratorial analysis of Interleukins</measure>
    <time_frame>01/07/2021</time_frame>
    <description>Number of participants with adverse events assessed by the interleukins analysis after SARS-CoV-2 infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal morphology ultrasound</measure>
    <time_frame>01/07/2021</time_frame>
    <description>Number of babies with developmental changes and fetal morphology alterations assessed by ultrasound after the maternal diagnosis of Covid-19.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placental insufficiency ultrasound</measure>
    <time_frame>01/07/2021</time_frame>
    <description>Number of participants with placental insufficiency and altered fetal well-being assessed by ultrasound after a positive maternal diagnosis of SARS-CoV-2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of delivery</measure>
    <time_frame>01/07/2021</time_frame>
    <description>Number of patients that performed natural delivery or caesarean, assessed by a structured questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational age at delivery</measure>
    <time_frame>01/07/2021</time_frame>
    <description>Gestational age at delivery and premature cases, assessed by a structured questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apgar score</measure>
    <time_frame>01/07/2021</time_frame>
    <description>Newborn's apgar score at first, second and third minutes after birth, assessed by a Apgar Score Scale (0 = minimum value and 10 = maximum value)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Newborn weight</measure>
    <time_frame>01/07/2021</time_frame>
    <description>Newborn's weight immediately after birth, assessed by a pediatric weight balance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Scale</measure>
    <time_frame>01/07/2021</time_frame>
    <description>Number of patients with persistent symptoms of fatigue, assessed by a Fatigue Structured Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prone Position</measure>
    <time_frame>01/07/2021</time_frame>
    <description>Number of patients who needed intervention with a prone position during hospitalization, accessed by the medical record data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of mechanical ventilation</measure>
    <time_frame>01/07/2021</time_frame>
    <description>Number of patients who needed intervention with a mechanical ventilation and oxygen during hospitalization, accessed by the medical record data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Ultrasound</measure>
    <time_frame>01/07/2021</time_frame>
    <description>Number of patients with alterations in pulmonary ultrasound and chest tomography resulting from SARS-Cov2 infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chest Tomography</measure>
    <time_frame>01/07/2021</time_frame>
    <description>Number of patients with alterations in pulmonary ultrasound and chest tomography resulting from SARS-Cov2 infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxious and depressive symptoms - HAD questionnaire</measure>
    <time_frame>01/07/2021</time_frame>
    <description>Number of patients with anxious and depressive symptoms in prenatal and postpartum, assessed by Hospital Anxiety and Depression Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability electrocardiogram</measure>
    <time_frame>01/07/2021</time_frame>
    <description>Number of patients with cardiac autonomic modulation, assessed by a heart rate variability electrocardiogram.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratorial analysis of glycated hemoglobin</measure>
    <time_frame>01/07/2021</time_frame>
    <description>Number of patients with endocrine system alterations after the Covid-19 infection, assessed by laboratorial analysis of glycated hemoglobin</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Pregnant Women</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Covid-19 HC patients</arm_group_label>
    <description>Pregnant women hospitalized with symptoms and diagnosis of SARS-CoV-2 at HC-FMUSP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delivery patients</arm_group_label>
    <description>Asymptomatic pregnant women that tested SARS-CoV-2 serology (positive or negative serology) at the delivery time at Universitarian Hospital HU-USP and HC-FMUSP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prenatal patients</arm_group_label>
    <description>Pregnant women that performs prenatal care in Universitarian Hospital HU-USP or HC-FMUSP with diagnosis of SARS-CoV-2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative serology patients</arm_group_label>
    <description>Pregnant women that performs prenatal care with symptoms and tested serology/swab negative for SARS-CoV-2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>SARS-CoV-2 serology</intervention_name>
    <description>Serology test of SARS-CoV-2 for pregnant women</description>
    <arm_group_label>Covid-19 HC patients</arm_group_label>
    <arm_group_label>Delivery patients</arm_group_label>
    <arm_group_label>Negative serology patients</arm_group_label>
    <arm_group_label>Prenatal patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women with clinical symptoms or positive serology for SARS-CoV-2 hospitalized, in&#xD;
        prenatal care, or in delivery time.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women with clinical symptoms or positive serology for SARS-CoV-2 hospitalized&#xD;
             or in delivery time;&#xD;
&#xD;
          -  Asymptomatic pregnant women for SARS-CoV-2 during pregnancy and hospitalized for&#xD;
             delivery at HU-USP.&#xD;
&#xD;
          -  Pregnant women diagnosed with SARS-CoV-2 prior to delivery and who, after the&#xD;
             quarantine period, followed prenatal care and delivered at the HU-USP or HCFMUSP.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-confirmation of maternal SARS-CoV-2 infection in pregnant women hospitalized or in&#xD;
             delivery time.&#xD;
&#xD;
          -  Withdrawal of pregnant woman to continue in the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rossana P Francisco, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculdade de Medicina da Universidade de São Paulo - FMUSP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rossana P Francisco, PhD</last_name>
    <phone>+551126616209</phone>
    <email>rossana.francisco@hc.fm.usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana Claudia S Farche, PhD</last_name>
    <phone>+551126619280</phone>
    <email>anafarche@usp.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rossana P Fracisco</name>
      <address>
        <city>São Paulo</city>
        <zip>05403000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rossana P Francisco, PhD</last_name>
      <phone>+551126616209</phone>
      <email>rossana.francisco@hc.fm.usp.br</email>
    </contact>
    <contact_backup>
      <last_name>Ana CS Farche, PhD</last_name>
      <phone>+551126619280</phone>
      <email>anafarche@usp.br</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>November 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2020</study_first_posted>
  <last_update_submitted>November 30, 2020</last_update_submitted>
  <last_update_submitted_qc>November 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pregnancy</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>vertical transmission</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

